IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Quality by Design (QbD)

Niket D. Bajare *, Pravin Rewale, Anshul Argulwar, Shubham Chidrewar ,Aishwarya Sawant.

Niket Bajare

School of Pharmacy,

Swami Ramanand Teerth Marathwada University, Nanded

ABSTRACT:

Quality by Design (QbD) be a concept first outlined by quality expert Joseph M. Juran in publications, most notably Juran on Quality intentionally. Designing for quality and innovation is one among the three universal processes of the Juran Trilogy, during which Juran describes what's required to realize breakthroughs in new products, services, and processes. QbD could be a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and method management supported sound science and quality risk management (ICH Q8(R)) QbD suggests that coming up with and developing formulations and manufacturing processes to make sure predefined product quality. Product quality is ensured by staple testing, drug substance manufacturing, a fixed drug product manufacturing process, in-process material testing, and end product testing. If they meet the manufacturer's proposed and FDA approved specifications or other standards like USP for drug substance or excipients, they can be used for the manufacturing of the products. The goal of a well-characterized method development effort is to develop a reliable method which will be demonstrated with a high degree of assurance to consistently produce data meeting predefined criteria when operated within defined boundaries. QbD are often applied to the event and evaluation of analytical methods. During method development, all potential factors (the inputs) and every one critical analytical responses (the outputs) are studied to work out the relationships.

KEYWORDS: Quality, QbD, FDA. CQA.

INTRODUCTION:

Quality by Design (QbD) be a concept first outlined by quality expert Joseph M. Juran in publications, most notably Juran on Quality intentionally. Designing for quality and innovation is one among the three universal processes of the Juran Trilogy, during which Juran describes what's required to realize breakthroughs in new products, services, and processes. Juran believed that quality might be planned, which most quality crises and problems relate to the way during which quality was planned. While Quality intentionally principles are wont to advance product and process quality in industry, and particularly the automotive industry, they need also been adopted by the U.S. Food and Drug Administration (FDA) for the invention, development, and manufacture of medicine [1, 2,].

The FDA imperative is printed in its report "Pharmaceutical Quality for the 21st Century: A Risk-Based Approach." within the past few years, the agency has implemented the concepts of QbD into its pre-market processes. The focus of this idea is that quality should be built into a product with an understanding of the merchandise and process by which it's developed and made along with knowledge of the risks involved in manufacturing the merchandise and the way best to mitigate those risks. The QbD initiative, which originated from the Office of Biotechnology Products (OBP), attempts to supply guidance on pharmaceutical development to facilitate design of products and processes that, maximizes the product's efficacy and safety profile while enhancing product manufacturability [3, 4].

The concept of QbD was mentioned within the ICH Q8guideline, which states that "quality can't be tested into products i.e., quality should be inbuilt intentionally ." consistent with ICH Q8 QbD is defined as a scientific approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, supported sound science and quality risk management. Quality intentionally (QbD) has become a replacement concept for development of quality pharmaceutical products, it's an important a part of the fashionable approach to pharmaceutical quality, QbD is a best solution to create a top quality altogether pharmaceutical products but it's also a serious challenge to the Pharmaceutical industry whose processes are fixed in time, despite inherent process and material variability, Under this concept of QbD throughout designing and development of a product, it is essential to define desire product performance profile [Target product Profile (TPP), Target Product Quality Profile (TPQP)] and identify critical quality attributed (CQA). On the idea of this we will design the merchandise formulation and process to satisfy the merchandise attributes. This results in recognize the impact of raw materials [critical material attributes (CMA), critical process parameters (CPP) on the CQAs and identification and control sources of variability. QbD is an emerging idea which offers pharmaceutical manufacturer with increased self-regulated flexibility while maintaining tight quality standards and real time release of the drug product.

Benefits of QbD [5,6]

- QbD is good Science

-Better development decisions

- Empowerment of technical staff

- Avoid regulatory compliance problems

- Organizational learning is an investment within the future

- QbD is good Business

- Eliminate batch failures

- Minimize deviations and costly investigations

Benefits to Industry [6]

-Ensures better design of products with less problems in manufacturing

-Reduces number of producing supplements required for post market changes –rely on process and risk understanding and risk mitigation

-Allows for implementation of latest technology to enhance manufacturing without regulatory scrutiny.

-Allows for possible reduction in overall costs of producing –less waste.

-Ensures less hassle during review –reduced deficiencies –quicker approvals.

- Improves interaction with FDA –deal on a science level rather than on a process level.

-Allows for continuous improvements in products and manufacturing process.

Opportunities [7, 8]

-economical, agile, versatile system

-Increase producing potency, scale back prices and
project rejections and waste

-Build knowledge domain base for all product

-higher move with business on science problems

-guarantee consistent info

- Incorporate risk management

Fig: Pharmaceutical Application of QBD.

Pharmaceutical Quality by Design

QbD could be a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and method management supported sound science and quality risk management (ICH Q8(R)) QbD suggests that coming up with and developing formulations and manufacturing processes to make sure predefined product quality. Thus, QbD needs associate Understanding and controlling formulation and producing method variables influence product quality. Relevant documents from the International Conference on Harmonization of Technical needs for Registration of prescribed drugs for Human Use (ICH), ICH Q8, Pharmaceutical Development, together with ICH Q9, Quality Risk Management, and ICH Q10, Pharmaceutical Quality Systems, indicate on associate abstract level however quality by design acts to make sure drug product quality.

ICH Q8 defines quality as "The suitableness of either a drug substance or drug product for its meant use. This term includes such attributes because the identity, strength, and purity." ICH Q6A emphasizes the role of specifications stating that "Specifications square measure important quality standards that square measure projected and even by the manufacturer and approved by restrictive authorities." Pharmaceutical QbD could be a systematic, scientific, risk-based, holistic and proactive approach to pharmaceutical development that begins with predefined objectives and emphases product and methods understanding and process management. It means coming up with and developing formulations and manufacturing processes to confirm predefined product quality objectives. QbD identifies characteristics that square measure critical to quality from the attitude of patients, translates them into the attributes

that the drug product should possess, and establishes however the important method parameters is varied to systematically manufacture a drug product with the required characteristics. so as to try and do this the relationships between formulation and manufacturing method variables (including drug substance and excipient attributes and method parameters) and products characteristics square measure established and sources of variability known. This information is then wont to implement a versatile and strong manufacturing method that may adapt and manufacture a consistent product over time [9, 10, 11].

Pharmaceutical Quality by Testing [12-18]

Product quality is ensured by staple testing, drug substance manufacturing, a fixed drug product manufacturing process, in-process material testing, and end product testing. If they meet the manufacturer's proposed and FDA approved specifications or other standards like USP for drug substance or excipients, they can be used for the manufacturing of the products. Since a couple of tablets out of several million are tested, drug manufacturers are usually expected to conduct extensive in process tests, such as blend uniformity, tablet hardness, etc; to ensure the outcome of in-process testing also meets the FDA approved in-process testing specifications. Manufacturers are also not permitted to make changes to the operating parameters specified in the batch record or other process changes without filing supplements with the FDA. As a result, the FDA has been overwhelmed by the number of Chemistry, Manufacturing, and Controls (CMC) supplements filed in recent years. For example, in 2005 and 2006, the FDA Office of Generic Drugs received over 3,000 CMC supplements annually. This combination of fixed manufacturing steps and extensive testing is what ensures quality under the traditional system. Limited characterization of variability, inadequate understanding to identify and quantify critical process parameters, and caution on the a part of regulators results in a really rigid and inflexible specifications that prohibit the release of products that may have acceptable clinical performance .Significant industry and FDA resources are spent debating issues related to acceptable variability, need for additional testing controls, and establishment of specification acceptance criteria. Often these debates are concentrated on acceptance limits or statistical aspects. FDA reviewers' conservatism results from the fact that manufacturers may not understand how drug substance, excipients, and manufacturing processes affect the quality of their products or they are doing not share this information with FDA reviewers. Under the traditional regulatory evaluation system, all products are treated equally without regard to the risk to the consumer. This has the effect of placing an excessive amount of review time on low-risk products and more significantly, takes away needed resources from the review of high-risk products. CMC review assessments of complex dosage forms (modified release products, topicals and transdermals) as well as narrow therapeutic index (NTI) drugs differ only marginally from those of simple dosage forms (many immediate release solid oral products). Further, all CMC information in applications are sometimes evaluated equally, without differentiation of criticality, resulting in the requirement of intensive resources for each application.

The Target Product Quality Profile (TPQP)[19,20]

The target product quality profile (TPQP) may be a quantitative surrogate for aspects of clinical safety and efficacy which will be wont to design and optimize a formulation and manufacturing process. International Society of Pharmaceutical Engineers (ISPE) Product Quality Lifecycle Implementation (PQLI) calls this the Pharmaceutical Target Product Profile. It should include quantitative targets for impurities and stability, release profiles (dissolution) and other product specific performance requirements. Product specific examples include resuspendability for an oral suspension, adhesion for a transdermal system, and viscosity for a topical cream. Generic products would come with bioequivalence to the RLD as a part of the TPQP. The TPQP isn't a specification because it includes tests like bioequivalence or stability that aren't administered in batch to batch release. The TPQP should only include patient relevant product performance. For example, if particle size is critical to the dissolution of a solid oral product, then the TPQP should include dissolution but not particle size. Particle size would be a critical material attribute and thus included within the process description and control strategy. The TPQP should be performance based and not mechanism based. samples of a TPQP are often found within the mock quality overall summary (QOS) presented on the Office of Generic Drugs website although the term TPQP wasn't clearly stated within the mock QOS. Another example of a TPQP is presented in the European Mock P2 that was developed to facilitate a scientific and regulatory dialogue between the Industry Association European Federation of Pharmaceutical Industries Associations, and Regulatory Authorities on the presentation of enhanced product and process understanding in regulatory dossiers. the ecu Mock P2 uses the nomenclature Target Product Profile, but their Table I fits our definition of a TPQP. They claim that the TPQP may be a definition of product intended use and a predefinition of quality targets (with reference to clinical relevance, efficacy and safety) and thus summarizes the standard attributes of the to provide safety and efficacy to the patient.

Formulation Design and Development [21]

Not all prototype formulations are often evaluated in human subjects, which mean that developing sensitive in vitro dissolution methods is crucial to an efficient development program. FDA's recommended in vitro dissolution method is usually used for internal control . Generic-drug sponsors report using in-house methods for pharmaceutical development (some mentioned using as many as five biorelevant dissolution conditions) to guage formulations and processes before performing bioequivalence studies. In current practice, pharmaceutical scientists develop a battery of biorelevant dissolution methods to accelerate drug-product development. Further, Biopharmaceutics arrangement is effective in guiding formulation development. To establish formulation robustness, sponsors of abbreviated new drug applications (ANDAs) generally evaluate relevant quality attributes of product manufactured at the laboratory scale. The availability of drug substance may influence the amount of studies and thus , product understanding. QbD should believe the relevance of

individual studies instead of the amount of studies because one among the objectives of QbD is to know how the fabric attributes of the drug substance and excipient influence product quality. Formulation design space (pre-approvedranges) would be valuable to industry if appropriate regulatory flexibility is granted. However,

the establishment of formulation design space shouldn't delay FDA's approvals. FDA considers the establishment of formulation design space as a post approval activity.

Manufacturing Process Design and Development [22, 23]

Process development and formulation design can't be separated because a formulation cannot become a product without a prescribed process. Process design is the initial stage of process development, during which an overview of the commercial manufacturing processes is documented, including the intended scales of manufacturing. The outline should include all the factors that need to be considered for the planning of the method , including facility, equipment, material transfer, and manufacturing variables. Other factors to consider during process development are the QTPP and CQAs. Depending upon the merchandise being developed, sort of process, and process knowledge the event scientists have, it's going to be necessary to conduct preliminary feasibility studies before completing the process development. The selection of the type of process depends upon the formulation and therefore the properties of the materials. Strictly speaking, process and product design and development can not be separated since a formulation can not become a product without a process. A formulation without a process is, for instance , a pile of powder. Process design is that the initial stage of process development where an overview of the commercial manufacturing processes is identified on paper, including the intended scales of manufacturing. this could include all the factors that require to be considered for the planning of the process, including facility, equipment, material transfer, and manufacturing variables. Other factors to think about for process design are the target product quality profiles. Depending upon the product being developed, sort of process, and process knowledge the event scientists have, it's going to be necessary to conduct preliminary feasibility studies before completing the process design and development. The selection of sort of process depends upon the merchandise design and the properties of the materials. For example, tablet manufacturing typically involves one of two methods: direct compression or granulation. Direct compression is the most straight forward, easiest to regulate , and least expensive tablet manufacturing process. It uses two primary unit operations, mixing and compression, to supply the finished tablet. Direct compression is employed when ingredients are often blended, positioned onto a tablet press, and made into a top quality tablet with none of the ingredients having to be changed. When powders are very fine, fluffy, won't stay blended, or won't compress, then they'll be granulated. Granulation is that the process of collecting particles together by creating bonds between them. Bonds are formed by compression or by employing a binding agent. Wet granulation, the process of adding a liquid solution to powders, is one among the foremost common ways to granulate. The dry granulation process is employed to make granules without employing a liquid solution. Forming granules without moisture requires compacting and densifying

the powders. Dry granulation can be conducted on a tablet press using slugging tooling, or more typically on a roller compactor.

Conclusion

The goal of a well-characterized method development effort is to develop a reliable method which will be demonstrated with a high degree of assurance to consistently produce data meeting predefined criteria when operated within defined boundaries. QbD are often applied to the event and evaluation of analytical methods. During method development, all potential factors (the inputs) and every one critical analytical responses (the outputs) are studied to work out the relationships. Critical analytical factors are identified in an approach that parallels what's described for process development in ICH Q8 and Q9. The QbD process on a lively partnership of analytical scientists at both the event and operational laboratories as methods are developed and as factors that cause potential method failures are identified and controlled. a company knowledge repository is required throughout the method to make sure critical information is captured which will be reviewed and added to within the future such lessons learned are often applied to the precise method into account and also to other similar methods being applied to other products. Such a repository (in line with concepts described within the draft ICH Q10) will enable continuous improvement and alter control of the tactic to require place throughout its lifecycle.

A QbD approach for analytical methods that has risk assessment, robustness testing, and ruggedness testing is much more rigorous than ICH validation requirements (Q2(R1)). It also includes an assessment of method variability compared with the specification limits, which is one of the foremost important method attributes to check when deciding whether the tactic is fit its purpose. The approach described herein suggests that ICH Q2(R1), while adding some value, must be substantially rewritten to take account of the QbD risk-based approaches described during this article. This new QbD process offers the chance for much greater regulatory flexibility within the future. the tactic performance criteria could potentially be registered instead of the tactic itself. the tactic used might be referred to as an example of the way to attain the specified method performance criteria. Any changes to the present method would be covered by internal change control procedures.

Reference

1. Juran, J.M. (1992). Juran on Quality by Design: The New Steps for Planning Quality into Goods and Services. Free Press.
2. Juran, J.M. (1986). "The Quality Trilogy: A Universal Approach to Managing for Quality". Quality Progress.
3. Pharmaceutical Quality for the 21st Century: A Risk-BasedApproach https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm128080.htm
4. "Process Validation: General Principles and Practices" (PDF). FDA Guidance. 2019-06-05.
5. Woodcock J, The concept of pharmaceutical quality. American Pharmaceutical Review, 7(6), 2004.
6. N. Vishal Gupta et al, International Journal of Drug Development and Research, 2015.
7. Callis JB, Illman DL, Kowalski BR, Process analytical chemistry. Analytical Chemistry, 1987, 624A–637A.
8. Yu LX, Pharmaceutical quality by design: Product and process development, understanding, and control. Pharmaceutical Research, 25, 2008, 781–791.
9. IBM Business Consulting Services Transforming industrialization: A new paradigm for pharmaceutical development http://www.ibm.com, transforming industrialization, 2006, 33.
10. Delasko J.M, Cocchetto D, Burke L.B, Target product profile: Beginning drug development with the end in mind, Jan/Feb2005; Issue 1.http://www.fdli.org.
11. Food and Drug Administration CDER, Draft guidance for industry and review staff: Target product profile-A strategic development tool, 2007, 7.
12. Nasr M, Risk-based CMC review paradigm, Advisory committee for pharmaceutical science meeting; 2004.
13. Food and Drug Administration CDER, Guidance for industry: Immediate release solid oral dosage forms scale-up and post approval changes: CMC, in vitro dissolution testing, and in vivo bioequivalence documentation, 1995.
14. Food and Drug Administration CDER, Guidance for industry: Modified release solid oral dosage forms scale-up and post approval changes: CMC, in vitro dissolution testing, and in vivo bioequivalence documentation, 1997.
15. Food and Drug Administration CDER, Guidance for industry: Non sterile semisolid dosage forms scale-up and post approval changes: chemistry, manufacturing, and controls, in vitro dissolution testing, and in vivo bioequivalence documentation, 1997.
16. Food and Drug Administration CDER, Guidance for industry: Changes to an approved NDA or ANDA, 2004.
17. Woodcock J, The concept of pharmaceutical quality, Am. Pharm Rev, 2004, 1–3.
18. Food and Drug Administration Office of Generic Drugs White Paper on Question-based Review: www.fda.gov.in.
19. Food and Drug Administration CDER. Draft guidance for industry and review staff,
Target product profile—A strategic development tool, 2007.

20. Food and Drug Administration Office of Generic Drugs. Model quality overall summary for IR product. http, //www.fda.gov/ cder/ogd/OGD_Model_ QOS_IR_Product.pdf, 2006.

21. Lawrence X, Furness M, Raw A, Woodland Outlaw K, Nashed N, Ramos E, Miller S, Adams R, Fang F, Patel R, Holcombe Jr F, Chiu Y, Hussain A. Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharm. Res 2003, 20, 531–536.

22. Tousey M. The granulation process 101, basic technologies for tablet making. Pharm. Tech. Tableting and Granulation, 2002.

23. Petrides D, Koulouris A, Lagonikos P. The Role of process simulation in pharmaceutical process development and product commercialization. Pharm. Eng 2002, 22, 1–8.